- Home
- APVO
as 04-01-2025 3:31pm EST
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 5.4M | IPO Year: | N/A |
| Target Price: | $296.00 | AVG Volume (30 days): | 83.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -87.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.94 - $180.19 | Next Earning Date: | 05-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Aptevo Therapeutics Inc. News
APVO Breaking Stock News: Dive into APVO Ticker-Specific Updates for Smart Investing
Benzinga
12 days ago
Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment
ACCESS Newswire
13 days ago
RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment
ACCESS Newswire
15 days ago
Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy
ACCESS Newswire
a month ago
Aptevo to Participate in March Conferences
ACCESS Newswire
a month ago
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ACCESS Newswire
2 months ago
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update
ACCESS Newswire
3 months ago
Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025
ACCESSWIRE
4 months ago
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds
Compare APVO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APVO Aptevo Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.